|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-12-12
|
|
pubmed:abstractText |
Preclinical models show sequence-dependent synergy with the combination of temozolomide and irinotecan, and a Phase I trial has demonstrated the combination to be tolerable and active in children with relapsed solid tumors. Because responses were seen in patients with Ewing sarcoma (ES) on that trial, additional patients were treated with this combination following study completion.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1545-5009
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
132-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16317751-Administration, Oral,
pubmed-meshheading:16317751-Antineoplastic Agents, Alkylating,
pubmed-meshheading:16317751-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:16317751-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16317751-Bone Neoplasms,
pubmed-meshheading:16317751-Camptothecin,
pubmed-meshheading:16317751-Child,
pubmed-meshheading:16317751-Dacarbazine,
pubmed-meshheading:16317751-Female,
pubmed-meshheading:16317751-Humans,
pubmed-meshheading:16317751-Injections, Intravenous,
pubmed-meshheading:16317751-Male,
pubmed-meshheading:16317751-Neoplasm Metastasis,
pubmed-meshheading:16317751-Sarcoma, Ewing
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
|
|
pubmed:affiliation |
Division of Hematology/Oncology, Primary Children's Medical Center, Salt Lake City, Utah, USA. lars.wagner@cchmc.org
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
